Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

NIH 2 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Hemangiosarcoma 2 Choriocarcinoma 2 Carcinoma, Non-Small-Cell Lung 2 Trophoblastic Tumor, Placental Site 1 Solid Tumors 1 Sarcoma 1 Ovarian Neoplasms 1 Glioblastoma 1 Gestational Trophoblastic Disease 1 Fallopian Tube Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1 Adult Solid Tumor 1

Interventions

Temozolomide 94 Radiotherapy 40 Bevacizumab 40 Lomustine 21 Radiation 18 Surgical Procedures, Operative 10 Carboplatin 9 pembrolizumab 8 Nivolumab 8 Carmustine 8 Irinotecan 7 IL13-PE38 6 Granulocyte-Macrophage Colony-Stimulating Factor 6 Flucytosine 6 Cyclophosphamide 6 ABT-414 6 vocimagene amiretrorepvec 5 depatuxizumab mafodotin 5 Valacyclovir 5 Drug Therapy 5 veledimex 4 sargramostim 4 enzastaurin 4 NVP-BKM120 4 Gemcitabine 4 Dianhydrogalactitol 4 Chlorotoxin 4 Aminolevulinic Acid 4 verubulin 3 selinexor 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Glioblastoma × carotuximab × Clear all

NCT01564914 2019-06-12

105GM201

Tracon Pharmaceuticals Inc.

Phase 2 Completed

22 enrolled 11 charts

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡